Clinical Trial

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is an open-label, multi-center Phase IB/II clinical trial of SHR-9839(sc) combined with anti-tumor therapy in patients with advanced solid tumors, aimed at evaluating the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor therapy in patients with advanced solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-13; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2026-03-10
Trial Details
NCT Number NCT07229638
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Solid Tumor
Enrollment 70 participants
Start Date 2026-02-27
Primary Completion 2027-04 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-20